Menu Search
Equities

CogState Ltd

COGZF:QXE

CogState Ltd

Actions
  • Price (USD)0.8581
  • Today's Change-0.039 / -4.29%
  • Shares traded1.00k
  • 1 Year change-13.32%
  • Beta--
Data delayed at least 15 minutes, as of May 02 2024 14:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cogstate Ltd is a neuroscience technology company. It is engaged in the creation, validation, and commercialization of digital brain health assessments and design and assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Research. The Clinical Trials segment includes adoption of decentralized clinical trial methodologies and scientific publication and marketing of the utility and validity of Cogstate technology. The Healthcare segment includes Cognigram, which allows for regular and standardized testing to assist in the early detection of cognitive decline that could be related to a range of factors including head injury, neurodegenerative disease or side effects following pharmacological treatments. The Research segment includes research studies and academic collaborations across various indications, such as Alzheimer’s disease and Parkinson’s disease.

  • Revenue in AUD (TTM)64.16m
  • Net income in AUD8.52m
  • Incorporated1999
  • Employees61.00
  • Location
    CogState LtdLevel 2, 161 Collins StreetMELBOURNE 3000AustraliaAUS
  • Phone+61 39664-1300
  • Fax+61 39664-1301
  • Websitehttps://cogstate.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.